cft

PPK-188, also known as CFT, is a novel selective covalent inhibitor of tryparedoxin (tpx), efficiently killing live african trypansosomes

CFT-0743 could inhibits tumor growth (81% regression) potently with PDC50 value of 0.18 nM.

CFT-1297 is a BET PROTAC degrader that targets BRD4 for degradation.

BETA-CFT sulfate is a derivative of BETA-CFT, an antagonist of dopamine transporter proteins (DATs).

CFT-2718 is an advanced BRD4-targeting PROTAC (proteolysis-targeting chimera) known for its improved catalytic efficiency and superior in vivo characteristics.

CFTR corrector 4 is a potent and orally available transmembrane conductance regulator (CFTR) for cystic fibrosis and is a potent (R,R) type active enantiomer. CFTR corrector 4 increases CFTR levels on the cell surface and is a potential compound for the study of cystic fibrosis.

CFTR corrector 12 is a CFTR corrector that rescues all mutant proteins except M760R ABCA3, and can be used to study cystic fibrosis.

CFTR corrector 8 is a highly effective modulator of the cystic fibrosis transmembrane conductance regulator (CFTR). This compound is specifically designed for utilization in research related to cystic fibrosis, a genetic disorder primarily affecting the lungs and digestive system [1].

CFTR(inh)-172 (CFTR Inhibitor-172) is a voltage-independent, selective CFTR inhibitor.

CFTR Corrector 9, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, is employed in the research of cystic fibrosis (CF) and related CFTR-associated disorders [1].

CFTR corrector 2 (FDL169) is a novel and potent CFTR (Cystic fibrosis transmembrane conductance regulator) corrector for treating cystic fibrosis (CF) patients who carry the F508del mutation.

CFT7455 (Cemsidomide) is an anti-cancer agent showing high affinity to the cereblon E3 ligase with a Kd of 0.9 nM. CFT7455 is an orally active degrader of zinc finger transcription factors Ikaros (IKZF1), and Aiolos (IKZF3).

CFTR Corrector 15 (Compound 4172) serves as a corrector for cystic fibrosis transmembrane conductance regulator (CFTR). When used in combination with VX-809, it addresses the folding defects of F508del-CFTR. CFTR Corrector 15 is also applicable in the research of cystic fibrosis.

CFTRcorrector 16 (Compound 39) is a corrector of the cystic fibrosis transmembrane conductance regulator (CFTR), utilized in the research of cystic fibrosis disease.

(S,R)-CFT8634 is a selective and orally active BRD9 protein degrader with potential for researching BRD9-mediated disorders, such as abnormal cellular proliferation [1].

CFT1946 is a Bifunctional Degradation Activating Compound (BiDAC) degrader that contains a ligand targeting the BRAF kinase domain linked to a cereblon ligand. CFT1946 is able to degrade BRAF V600E (class I), G469A (class II), G466V (class III) mutations and p61-BRAFV600E splice variants while maintaining excellent selectivity for the proteome including WT BRAF and CRAF.

CFTRcorrector 14 (Compound SVQ26) functions as a Class 3 corrector targeting the cystic fibrosis transmembrane conductance regulator (CFTR), enhancing CFTR activity (improving activity in the presence of Class 1 corrector VX-809 with an EC50 of 3.08 μM). It addresses the misfolding and functional impairments of CFTR proteins caused by mutations. CFTRcorrector 14 is used in cystic fibrosis research.

CFT8634 is an orally active and selective degrader targeting BRD9, with effects on the proliferation of SMARCB1-deficient cancer cell lines. CFT8634 induces the formation of a ternary complex with BRD9 and E3 ligase, inducing BRD9 ubiquitination and subsequent degradation by the proteasome.

CFTRcorrector 13 (SVQ18) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector with an EC50 value of 3.14 μM. This compound enhances the function of CFTR channels, particularly when used in conjunction with Lumacaftor, leading to a dose-dependent increase in CFTR activity. CFTRcorrector 13 is utilized in research related to cystic fibrosis (CF) and other CFTR-associated diseases.

CFTRcorrector 17 (example 17) is a regulator of the cystic fibrosis transmembrane conductance regulator (CFTR). It is utilized in the study of diseases mediated by CFTR.

CFTR corrector 6 is a highly effective CFTR potentiator utilized in research on cystic fibrosis (CF) and related CFTR-associated disorders[1]. This potent compound exhibits potentiation activity on the Cystic Fibrosis Transmembrane conductance Regulator (CFTR), rendering it beneficial for investigations in CF and other associated conditions.

CFTRactivator 2 (WAY-326769) acts as an activator for the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR).

(Rac)-CFT7455 is an Ikaros Aiolos degradation agent that acts via the ubiquitin proteasome pathway and is able to act on NCIH929.1 cells (GI50: 0.05 nM). (Rac)-CFT7455 is a racemic isomer of CFT7455 and has anticancer activity.

PROTAC BRD4 ligand-2 is a ligand for the target BRD4 protein used in the development of PROTAC CFT-2718.